It has been well established that activation of TLR4 by microbial endotoxin, LPS (TLR4 agonist), triggers the host's innate immune and inflammatory responses leading to the upregulation of pathways relating to insulin resistance and dyslipidemia. Here, TLR4 is linked to Insulin resistance.